Pliant Therapeutics Q1 net loss narrows to $20.0 million from $56.2 million
Pliant Therapeutics reported first quarter 2026 results on May 11, 2026, with a net loss of $20.0 million, compared with $56.2 million a year earlier. The company said the decline was driven mainly by lower operating expenses after it terminated bexotegrast development in idiopathic pulmonary fibrosis (IPF) in 2025, along with reduced personnel costs. Cash, cash equivalents and short-term investments were $172.4 million at March 31, 2026, which the company expects to fund operations into the second half of 2028.
Key points
- Net loss was $20.0 million, or $0.32 per share, versus $56.2 million, or $0.92 per share, in the first quarter of 2025.
- Research and development expenses were $13.6 million, down from $43.4 million, mainly due to completing BEACON-IPF close-out activities in 2025.
- General and administrative expenses were $8.2 million, down from $15.5 million, mainly due to lower personnel-related costs.
- First participant was dosed in the FORTIFY Phase 1b trial in April 2026; interim data are expected in 2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.